Medical Devices



BREVITEST TECHNOLOGIES is developing a biomedical immunoassay platform technology that could allow consumers, patients, caregivers, and others to more easily detect and quantify molecules of interest from a variety of sample types like blood, saliva, urine and water. This is a compact, portable, point-of-care device that is sensitive, specific and rapid. This is a broadly applicable platform technology targeted towards markets with an unmet need for a sensitive, easy to use, point of care method to quantify molecules. Potential markets include physician’s office laboratories for immediate testing of disease markers like PSA or TSH, hospitals for bedside testing, drug titration and emergency diagnostics in the ER, veterinary testing, population screening for endemic diseases or outbreaks, and consumer health testing for home health or lifestyle applications.


This platform technology can test for a variety of analytes, including proteins, small molecules, and serum antibodies (serology). It is accurate, rapid (runtime of less than 15 minutes, portable (less than 6” in any dimension), economical (cost per test to be significantly lower than reimbursement levels), user-friendly (one-step completely automated testing), complete system (analyzer performs entire ELISA, including optical reading and data upload to cloud with no additional equipment needed), and secure (data accessible only to indivuduals with appropriate permissions).

Contact us for more information.



CHORIOANCHOR Our ChorioAnchor device provides a way of securing the chorioamniotic membranes of pregnant mothers to the uterine wall to prevent preterm premature rupture of the membranes (pPROM), which can lead to complications for the mother and her baby. The current method for reducing the risk of pPROM is to make an open incision in the mother’s abdomen to gain access to the uterus and suture the membranes to the uterine wall. However, the skin incision requires the procedure to be performed under general anesthesia, increasing the risk of harm to the mother and baby. The ChorioAnchor device has the potential to assist in surgeries to correct congenital defects, such as Spina Bifida, and is one of the first devices under development for the relatively new field of fetal surgery.

Contact us for more information.



CYGNET MEDICAL DIAGNOSTICS- The Cygnet catheter system is a novel catheter and deployment system that will permit right heart catheterization (RHC) in the cardiologist’s office. Pulmonary hypertension (PH) is diagnosed by measuring mean Pulmonary Artery Pressure (mPAP) using RHC; however, this method requires the patient to be sedated and supine, and thus largely overlooks the mPAP of exercise-induced PH resulting in an inaccurate or delayed diagnosis. Currently, RHC is only performed in specialized catheterization labs under conditions of stringent sterility and with a large, trained team. Cygnet will enable exercise mPAP measurements for a more accurate diagnoses of pulmonary hypertension and also improve the speed and efficiency of RHC.

Contact us for more information.



SECURINE- Urinary incontinence is a major problem in pediatric patients with neurogenic bladder. The current standard of care is a combination of oxybutynin, a drug that reduces bladder muscle overactivity, and intermittent catheterization approximately 4-6 times a day. However, catheterization can be cumbersome, uncomfortable, and increase bladder infection risk. In addition to this, very often, there is still leakage of urine between catheterizations leading to significant emotional distress and other health-related issues. Our device aims to replace catheterization and prevent leakage so patients have more control over their bladder and an improved quality of life.

Contact us for more information.

Spin-Out Companies



We are actively developing a number of “stealth” technologies which are not yet listed on our website.

Contact Us


Contact Us About Your Technology

Contact Us